Meeting
2011 ASCO Annual Meeting
CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naïve patients with FLT3 mutated AML.
Authors
R. M. Stone
Dana-Farber Cancer Institute, Boston, MA
R. M. Stone , H. Dohner , G. Ehninger , M. Villeneuve , T. Teasdale , J. D. Virkus , L. R. Bressler , M. M. Seiler , G. Marcucci , R. A. Larson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00651261
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS199)
Abstract #
TPS199
Poster Bd #
48E
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.
First Author: Richard M. Stone
Poster
2018 ASCO Annual Meeting
Trial in progress: An open-label, multicenter, phase 3b study to assess the safety and efficacy of midostaurin in patients (pts) aged ≥ 18 y with newly diagnosed (ND) FLT3-mutated acute myeloid leukemia (AML) who are eligible for 7+3 or 5+2 chemotherapy (chemo).
First Author: Adolfo Fuentes
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey
Poster
2021 ASCO Annual Meeting
Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
First Author: Vinod Pullarkat